{"news_desk": "Business", "print_page": "", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By ROBERT CYRAN", "person": [{"rank": 1, "role": "reported", "firstname": "Robert", "organization": "", "lastname": "CYRAN"}]}, "abstract": null, "type_of_material": "News", "word_count": "391", "lead_paragraph": "There is relief among Valeant\u2019s backers that the company has returned to signing deals, after its long chase of Allergan left it empty-handed.", "pub_date": "2015-02-24T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Valeant\u2019s Deal for Salix Continues Frenzied Deal-Making in Drug Sector", "content_kicker": "Breakingviews", "kicker": "Breakingviews"}, "snippet": "There is relief among Valeant\u2019s backers that the company has returned to signing deals, after its long chase of Allergan left it empty-handed.", "multimedia": [], "web_url": "http://www.nytimes.com/2015/02/24/business/dealbook/valeants-deal-for-salix-continues-frenzied-deal-making-in-drug-sector.html", "keywords": [{"rank": "1", "is_major": "N", "value": "Mergers, Acquisitions and Divestitures", "name": "subject"}, {"rank": "2", "is_major": "N", "value": "Salix Pharmaceuticals Ltd", "name": "organizations"}, {"rank": "3", "is_major": "N", "value": "Valeant Pharmaceuticals International Inc", "name": "organizations"}, {"rank": "4", "is_major": "N", "value": "Drugs (Pharmaceuticals)", "name": "subject"}], "blog": [], "_id": "54eb818e38f0d87adf6b3c32", "source": "The New York Times"}